Role of tamsulosin, solifenacin, and combination therapy in the management of Double J stent related symptoms

Abstract

Ureteral stents, which were introduced by Zimskind et al in 1967, are widely used for urinary tract disease.1 The double-J stent, which is the most common form of ureteral stent, is used in obstructive pyelonephritis, intolerable acute renal colic, ureteral edema, ureter perforation following endoscopic procedures, and diseases such as stein- strasse.2,3 Despite the usefulness of stents, however, patients experience various stent-related symptoms, such as pain, frequency and urgency, which cause a significant decrease in patient health-related quality of life (HRQoL).4.